Connect your AI

Regenxbio RGNX Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Regeneron PharmaceuticalsREGN

——

Sarepta Therapeutics, Inc.SRPT

——

4D Molecular TherapeuticsFDMT

——

Sutro BiopharmaSTRO

——

Arrowhead ResearchARWR

——

Other financials

Income statement

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Regenxbio's accrued progress collections and price adjustments?: Regenxbio (RGNX) reported accrued progress collections and price adjustments of $22.78M in Q1 2026.
How has Regenxbio's accrued progress collections and price adjustments changed year-over-year?: Regenxbio's accrued progress collections and price adjustments decreased by 13.4% year-over-year, from $26.3M to $22.78M.